Tehohoito
Taloudelliset tulokset
Restrictive blood transfusion practices are associated with improved patient outcomes. (avaa uuden ikkunan)
Lähde: Transfusion 2014;54(10 Pt 2):2753-9.
Arkistoitu: PubMed 24995770
DOI: 10.1111/trf.12723
https://www.ncbi.nlm.nih.gov/pubmed/24995770 (avaa uuden ikkunan)
Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. (avaa uuden ikkunan)
Lähde: Transfusion 2017;57(6):1347-58.
Arkistoitu: PubMed 28150313
DOI: 10.1111/trf.14006
https://www.ncbi.nlm.nih.gov/pubmed/28150313 (avaa uuden ikkunan)
Cost-effectiveness of recombinant human erythropoietin for reducing red blood cells transfusions in critically ill patients. (avaa uuden ikkunan)
Lähde: Value Health 2005;8(2):105-16.
Arkistoitu: PubMed 15804319
DOI: 10.1111/j.1524-4733.2005.04006.x
https://www.ncbi.nlm.nih.gov/pubmed/15804319 (avaa uuden ikkunan)
Implementation of a patient blood management monitoring and feedback program significantly reduces transfusions and costs. (avaa uuden ikkunan)
Lähde: Transfusion 2015;55(12):2807-15.
Arkistoitu: PubMed 26264557
DOI: 10.1111/trf.13260
https://www.ncbi.nlm.nih.gov/pubmed/26264557 (avaa uuden ikkunan)
Trauma-induced coagulopathy: impact of the early coagulation support protocol on blood product consumption, mortality and costs. (avaa uuden ikkunan)
Lähde: Crit Care 2015;19:83.
Arkistoitu: PubMed 25880548
DOI: 10.1186/s13054-015-0817-9
https://www.ncbi.nlm.nih.gov/pubmed/25880548 (avaa uuden ikkunan)
The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients. (avaa uuden ikkunan)
Lähde: Health Technol Assess 2013;17(10):1-79.
Arkistoitu: PubMed 23477634
DOI: 10.3310/hta17100
https://www.ncbi.nlm.nih.gov/pubmed/23477634 (avaa uuden ikkunan)
Reversal of coagulopathy in critically ill patients with traumatic brain injury: recombinant factor VIIa is more cost-effective than plasma. (avaa uuden ikkunan)
Lähde: J Trauma 2009;66(1):63-72.
Arkistoitu: PubMed 19131807
DOI: 10.1097/TA.0b013e318191bc8a
https://www.ncbi.nlm.nih.gov/pubmed/19131807 (avaa uuden ikkunan)
Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation. (avaa uuden ikkunan)
Lähde: BMC Health Serv Res 2007;7:138.
Arkistoitu: PubMed 17764560
DOI: 10.1186/1472-6963-7-138
https://www.ncbi.nlm.nih.gov/pubmed/17764560 (avaa uuden ikkunan)